These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12039429)

  • 41. Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease.
    Manza P; Schwartz G; Masson M; Kann S; Volkow ND; Li CR; Leung HC
    Neurobiol Aging; 2018 Jun; 66():12-22. PubMed ID: 29501966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease.
    Rey RD; Garretto NS; Bueri JA; Simonetti DD; Sanz OP; Sica RE
    Electromyogr Clin Neurophysiol; 1996 Sep; 36(6):357-60. PubMed ID: 8891475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polyneuropathy in levodopa-treated Parkinson's patients.
    Szadejko K; Dziewiatowski K; Szabat K; Robowski P; Schinwelski M; Sitek E; Sławek J
    J Neurol Sci; 2016 Dec; 371():36-41. PubMed ID: 27871444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Basal ganglia, Parkinson's disease and levodopa therapy. Proceedings of a meeting. St Thomas, Virgin Islands, January 2000.
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S1-126. PubMed ID: 11221749
    [No Abstract]   [Full Text] [Related]  

  • 47. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
    Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical predictive factors of subthalamic stimulation in Parkinson's disease.
    Welter ML; Houeto JL; Tezenas du Montcel S; Mesnage V; Bonnet AM; Pillon B; Arnulf I; Pidoux B; Dormont D; Cornu P; Agid Y
    Brain; 2002 Mar; 125(Pt 3):575-83. PubMed ID: 11872614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
    Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
    Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
    Nomoto M; Iwaki H; Kondo H; Sakurai M
    J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 54. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
    Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
    Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Objective Gait and Balance Impairments Relate to Balance Confidence and Perceived Mobility in People With Parkinson Disease.
    Curtze C; Nutt JG; Carlson-Kuhta P; Mancini M; Horak FB
    Phys Ther; 2016 Nov; 96(11):1734-1743. PubMed ID: 27149959
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of age and disease duration on parkinsonian motor scores under levodopa therapy.
    Ransmayr G; Künig G; Neubauer M; Wagner M; Falk M
    J Neural Transm Park Dis Dement Sect; 1995; 9(2-3):177-88. PubMed ID: 8527002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.